The role of Akkermansia muciniphila in inflammatory bowel disease: Current knowledge and perspectives

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, is a chronic relapsing gastrointestinal inflammatory disease mediated by dysregulated immune responses to resident intestinal microbiota. Current conventional approaches including aminosalicylates, corticosteroids, immunosuppressive agents, and biological therapies are focused on reducing intestinal inflammation besides inducing and maintaining disease remission, and managing complications. However, these therapies are not curative and are associated with various limitations, such as drug resistance, low responsiveness and adverse events. Recent accumulated evidence has revealed the involvement of mucin-degrading bacterium <i>Akkermansia muciniphila</i> (<i>A. muciniphila</i>) in the regulation of host barrier function and immune response, and how reduced intestinal colonisation of probiotic <i>A. muciniphila</i> can contribute to the process and development of inflammatory bowel diseases, suggesting that it may be a potential target and promising strategy for the therapy of inflammatory bowel disease. In this review, we summarise the current knowledge of the role of <i>A. muciniphila</i> in IBD, especially focusing on the related mechanisms, as well as the strategies based on supplementation with <i>A. muciniphila</i>, probiotics and prebiotics, natural diets, drugs, and herbs to promote its colonisation in the gut, and holds promise for <i>A. muciniphila</i>-targeted and -based therapies in the treatment of inflammatory bowel disease.